[Article Summary] For over a decade, the intravitreal injection has been the gold standard for treating a multitude of retinal diseases, saving the sight of millions worldwide. However, the high treatment burden of frequent, often monthly or bi-monthly, injections remains a significant challenge for patients and practices alike. Now, a new wave of innovation in drug delivery—from refillable implants and biodegradable systems to the ultimate goal of gene therapy—is poised to revolutionize the standard of care once again, promising a future of greater durability, reduced clinical burden, and more personalized therapeutic approaches. This evolution is a key component of the broader retina innovation pipeline.
The Challenge of Treatment Burden: A Multifaceted Problem
The efficacy of modern biologic drugs for retinal conditions, particularly anti-VEGF agents for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), is undeniable. However, this efficacy is inextricably linked to a demanding and often indefinite schedule of injections. This creates a significant “treatment burden” that affects all stakeholders:
- For Patients: Frequent clinic visits lead to time away from work or family, transportation challenges, anxiety associated with injections, and the psychological toll of chronic disease management. Non-adherence due to this burden can lead to suboptimal visual outcomes.
- For Practices: Managing the high volume and logistical complexity of frequent injection clinics strains resources, impacts staffing for success, and can lead to operational bottlenecks. The buy-and-bill model also means significant inventory management and financial risk.
- For Payers: While effective, the cumulative cost of frequent injections over many years is substantial.
As noted in a 2025 review by Dr. Dario Rusciano, a primary goal of modern ophthalmic research is to develop innovative drug delivery systems that can overcome these challenges by enhancing bioavailability and providing sustained release [1]. Addressing this treatment burden is the single most important driver of innovation in retinal drug delivery today.
The Rise of Sustained Delivery: Extending the Interval
The first wave of solutions has focused on creating reservoirs and novel formulations that can store and slowly release medication over time, dramatically reducing the number of required office visits. These approaches aim to solve the problem of rapid drug clearance from the vitreous humor, which necessitates frequent re-dosing.
- Biodegradable Implants: These systems are designed to be injected into the eye (or surgically placed) and slowly release a drug over several months, eventually dissolving completely without the need for surgical removal.
- Examples: The dexamethasone implant (Ozurdex) releases a corticosteroid for up to 6 months for macular edema. Fluocinolone acetonide implants (Iluvien, Yutiq) provide sustained steroid release for up to 3 years for chronic DME or non-infectious uveitis.
- Strategic Impact: These reduce injection frequency, improve patient adherence, and offer a more consistent therapeutic effect compared to bolus injections. For practices, they simplify scheduling and potentially reduce the administrative burden associated with frequent visits.
- Refillable Implants: These represent a more ambitious approach, involving a surgically placed device that can be refilled in an office setting.
- Example: The Port Delivery System (PDS) for ranibizumab (Susvimo) was a landmark in this area, designed to extend the treatment interval for nAMD to many months. While it faced market challenges, the underlying concept of a long-term, refillable reservoir remains highly attractive.
- Strategic Impact: Such systems fundamentally shift the patient journey and practice workflow. They move from high-volume, frequent injections to less frequent, but potentially higher-value, office-based refill procedures. This requires adapting clinical protocols, patient education, and billing practices.
- Novel Formulations: Beyond implants, research is heavily focused on new ways to package drugs to extend their vitreous half-life.
- Examples: As detailed in the “Personal Scientific Journey” review, innovative systems like nanomicelles, liposomal sprays, and other polymer-based formulations are being developed to enhance ocular bioavailability and provide more controlled, sustained release of therapeutics [1]. These could potentially be delivered via standard intravitreal injection but offer significantly longer duration of action.
- Strategic Impact: These formulations aim to provide the convenience of less frequent injections without the need for surgical implantation, offering a less invasive path to extended durability.
“Our Take”
Our Take: The move toward sustained delivery is more than just a matter of convenience; it represents a fundamental shift in the business model of a retina practice. While these technologies will reduce the sheer volume of injections, they will also create new revenue streams from surgical implantation and in-office refills. The practices that will thrive are those that can adapt their clinical workflows and financial models to embrace this new, less frequent, but higher-value standard of care.
Enjoying this article? The future of retina is in sight. Subscribe to our weekly “Retina Roundup.”
On the Horizon: Gene Therapy and Beyond – The Ultimate Durability
The next frontier in drug delivery aims to eliminate the need for repeated treatments altogether by turning the eye into its own “bio-factory,” continuously producing the therapeutic protein.
- The Gene Therapy Concept: The concept behind gene therapy for retinal disease is elegant and powerful. A harmless, adeno-associated virus (AAV) is engineered to carry the genetic code for producing a therapeutic protein, such as an anti-VEGF agent or a protein to correct a genetic defect. As described in a 2025 review in the Journal of Medical Virology, AAV is recognized as a safe and effective method for delivering these transgenes, offering the potential for long-lasting gene expression with low immune response [3]. A single, one-time injection could, in theory, provide years of continuous treatment, or even a cure for certain inherited retinal diseases.
- The AAV Revolution and Challenges: AAV-based gene therapy is already a clinical reality for some conditions (e.g., Luxturna for Leber congenital amaurosis). The eye is an ideal target for this approach due to its immune-privileged and compartmentalized nature, which minimizes systemic side effects. However, significant challenges remain, including:
- Limited Packaging Capacity: The AAV vector has a limited capacity for the genetic material it can carry.
- Pre-existing Immunity: Many individuals have pre-existing antibodies to common AAV serotypes, which can neutralize the viral vector and reduce treatment efficacy.
- Manufacturing Complexity: Scaling up manufacturing for gene therapies is complex and costly.
- Long-Term Durability: While promising, the exact duration of effect and potential for waning efficacy over many years are still being studied.
- A Strategic Framework for the Future: The development of gene therapies cannot be haphazard. A 2025 review in the Journal of Ophthalmology proposes a strategic, data-driven framework for identifying the best candidate genes for this approach [2]. This involves integrating data on global disease prevalence, the burden of specific genetic mutations, and the technical feasibility of delivering the gene with current vector technology. This systematic approach is essential for prioritizing targets that are not only scientifically promising but also clinically impactful and scalable [2].
Conclusion: A Diverse Toolkit for Personalized Care
The high treatment burden associated with frequent anti-VEGF injections is the primary catalyst for innovation in retinal drug delivery. This has led to a multi-pronged approach:
- Sustained-release technologies, from biodegradable implants to novel nanoparticle formulations, are the first wave of solutions already changing clinical practice, offering intervals of several months.
- Gene therapy, delivered via AAV vectors, represents the next frontier, with a systematic, data-driven approach now guiding the selection of the most promising targets to create durable, long-lasting treatments, potentially offering years of effect or even cures.
The future of retina care will involve a diverse toolkit of therapeutic options, allowing specialists to tailor treatment not just to a patient’s disease and its activity, but also to their lifestyle, preferences, and ability to manage a long-term treatment schedule. This personalized approach promises to improve patient outcomes, enhance quality of life, and optimize the operational efficiency of retina practices.
Works Cited
[1] Rusciano, D. “A Personal Scientific Journey in Ophthalmology: Twenty-Five Years of Translating Research into Novel Therapies.” Pharmaceuticals (Basel), vol. 18, no. 6, 2025, p. 883., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12195827/. Accessed June 30, 2025.
[2] Wang, C. Y., et al. “Systematic Identification of Candidate Genes for Inherited Retinal Disease Gene Therapy Integrating Worldwide IRD Cohort and Single-Cell Analysis.” Journal of Ophthalmology, vol. 2025, 2025, p. 7014745., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178778/. Accessed June 30, 2025.
[3] Yin, L., et al. “Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application.” Journal of Medical Virology, vol. 97, no. 6, 2025, p. e70447., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178111/. Accessed June 30, 2025.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.